Sandra E. Dillahunt

Array ( [id] => 13413265 [patent_doc_number] => 20180258175 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-13 [patent_title] => ANTI-CD115 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 15/760322 [patent_app_country] => US [patent_app_date] => 2016-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16195 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15760322 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13413265 [patent_doc_number] => 20180258175 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-13 [patent_title] => ANTI-CD115 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 15/760322 [patent_app_country] => US [patent_app_date] => 2016-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16195 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15760322 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13400011 [patent_doc_number] => 20180251548 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-06 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING CANCER VIA ANTAGONISM OF THE CD155/TIGIT PATHWAY AND TGF-BETA [patent_app_type] => utility [patent_app_number] => 15/758090 [patent_app_country] => US [patent_app_date] => 2016-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31637 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -65 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15758090 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13986587 [patent_doc_number] => 20190062451 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2019-02-28 [patent_title] => PCSK9 ANTIBODY PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE [patent_app_type] => utility [patent_app_number] => 15/260260 [patent_app_country] => US [patent_app_date] => 2016-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32981 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15260260 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13986587 [patent_doc_number] => 20190062451 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2019-02-28 [patent_title] => PCSK9 ANTIBODY PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE [patent_app_type] => utility [patent_app_number] => 15/260260 [patent_app_country] => US [patent_app_date] => 2016-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32981 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15260260 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17602919 [patent_doc_number] => 11331388 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-05-17 [patent_title] => PTP4A1 as a therapeutic target for fibrotic diseases and disorders including systemic sclerosis [patent_app_type] => utility [patent_app_number] => 15/257587 [patent_app_country] => US [patent_app_date] => 2016-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 89 [patent_no_of_words] => 22916 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15257587 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11471254 [patent_doc_number] => 20170058036 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-02 [patent_title] => 'ANTI-DEspR MONOCLONAL ANTIBODY TARGETED THERAPY AND IMAGING FOR CANCER AND STROKE' [patent_app_type] => utility [patent_app_number] => 15/245853 [patent_app_country] => US [patent_app_date] => 2016-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 54 [patent_no_of_words] => 71230 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15245853 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13297681 [patent_doc_number] => 20180200377 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-19 [patent_title] => MULTI-LIGAND DRUG CONJUGATES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/751541 [patent_app_country] => US [patent_app_date] => 2016-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17603 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15751541 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13358011 [patent_doc_number] => 20180230545 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-16 [patent_title] => Method for the prediction of progression of bladder cancer [patent_app_type] => utility [patent_app_number] => 15/750508 [patent_app_country] => US [patent_app_date] => 2016-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9349 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15750508 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11706258 [patent_doc_number] => 20170174758 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-22 [patent_title] => 'THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE' [patent_app_type] => utility [patent_app_number] => 15/220249 [patent_app_country] => US [patent_app_date] => 2016-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 46 [patent_no_of_words] => 23961 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15220249 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11107910 [patent_doc_number] => 20160304881 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-20 [patent_title] => 'DDR1 ANTAGONIST OR AN INHIBITOR OF DDR1 GENE EXPRESSION FOR USE IN THE PREVENTION OR TREATMENT OF CRESCENTIC GLOMERULONEPHRITIS' [patent_app_type] => utility [patent_app_number] => 15/200014 [patent_app_country] => US [patent_app_date] => 2016-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10310 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15200014 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11514325 [patent_doc_number] => 20170081399 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-23 [patent_title] => 'THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE' [patent_app_type] => utility [patent_app_number] => 15/192915 [patent_app_country] => US [patent_app_date] => 2016-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 47 [patent_no_of_words] => 23841 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15192915 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13574829 [patent_doc_number] => 20180338963 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-29 [patent_title] => DONOR ORGAN PRE-TREATMENT FORMULATION [patent_app_type] => utility [patent_app_number] => 15/745913 [patent_app_country] => US [patent_app_date] => 2016-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14453 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15745913 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18202414 [patent_doc_number] => 11584797 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-21 [patent_title] => Inhibition of CCL5 ligand binding to CCR5 receptor and alteration of CCR5/CCL5 axis signaling in inflammation, cancer, autoimmune, and other conditions [patent_app_type] => utility [patent_app_number] => 15/737706 [patent_app_country] => US [patent_app_date] => 2016-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 5247 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15737706 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13586529 [patent_doc_number] => 20180344813 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION WITH REDUCED IMMUNOGENICITY [patent_app_type] => utility [patent_app_number] => 15/177397 [patent_app_country] => US [patent_app_date] => 2016-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45737 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15177397 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19563531 [patent_doc_number] => 12138282 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-12 [patent_title] => Treatment with an IL-2 based therapy [patent_app_type] => utility [patent_app_number] => 15/579186 [patent_app_country] => US [patent_app_date] => 2016-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 98 [patent_figures_cnt] => 102 [patent_no_of_words] => 22784 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 248 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15579186 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11336714 [patent_doc_number] => 20160362469 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-15 [patent_title] => 'Methods for protein modification in pharmaceutical applications' [patent_app_type] => utility [patent_app_number] => 15/169640 [patent_app_country] => US [patent_app_date] => 2016-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 11433 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15169640 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18683891 [patent_doc_number] => 11779601 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-10 [patent_title] => Diagnostic methods for T cell therapy [patent_app_type] => utility [patent_app_number] => 15/577672 [patent_app_country] => US [patent_app_date] => 2016-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 105 [patent_no_of_words] => 31213 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 157 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15577672 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18117559 [patent_doc_number] => 11548940 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-10 [patent_title] => Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device [patent_app_type] => utility [patent_app_number] => 15/150379 [patent_app_country] => US [patent_app_date] => 2016-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 51 [patent_figures_cnt] => 59 [patent_no_of_words] => 31254 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15150379 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18117559 [patent_doc_number] => 11548940 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-10 [patent_title] => Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device [patent_app_type] => utility [patent_app_number] => 15/150379 [patent_app_country] => US [patent_app_date] => 2016-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 51 [patent_figures_cnt] => 59 [patent_no_of_words] => 31254 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15150379 [rel_patent_id] =>[rel_patent_doc_number] =>)